Rana Lonnen

We believe clinical research can be built to improve health equity globally. Learning if treatments are safe and effective for the people who need them requires us to offer studies that are more accessible and offer choice. We founded Lightship in 2018 with the inspiration to keep people at the heart of our work and use the latest innovations in digital health, technology, and remote care melded with high quality clinical research to transform clinical trials. Our approach offers clinical trials that are designed from the beginning to make it easier for patients and caregivers to take part. By using inclusive technology, flexible visit types, an amazing experience, and commitment to quality, we can develop programs to better bring new potentially life-saving therapies into the world, together.

Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave is currently collaborating with leading clinics, payers, and pharma companies across the country.

Healthcare providers no longer have to go to multiple portals or chase down the appropriate paperwork to complete the enrollment process. RxLightning serves as a single destination for healthcare providers to enroll patients for any specialty medication, brand or generic, at any specialty pharmacy. We strive to improve speed of access for patients to specialty medications, accelerating the delivery of your specialty products and maximizing your revenue stream. Our platform is a single solution that simplifies, streamlines and automates the complex and manual process of specialty medication enrollment across manufacturers, hubs, and specialty pharmacies. Specialty prescribing is complex. We make it simple. Digitized forms for 1,200+ specialty medications to get your patients started on the therapies they need at RxLightning speed. To view our open positions, view our careers page: https://jobs.gusto.com/boards/rxlightning-inc-2ba76134-6085-4789-bec7-35312efef93e

Holmusk is a data analytics and health technology company on a mission to harness real-world evidence to transform both research and care for behavioral health. Combining a leading behavioral health database with AI-powered analytics and digital solutions designed to address the most pressing challenges in behavioral health, Holmusk is advancing the frontier of evidence generation and fueling innovation. Holmusk’s core offerings include HolCare EHR+, an electronic health records platform with built-in measurement-based care, and NeuroBlu Research, a powerful data analytics solution that enables users to build patient cohorts, explore datasets, and discover new insights. Founded in 2015, Holmusk is a global company headquartered in Singapore and New York. Holmusk was recognized as a Technology Pioneer in 2019 by the World Economic Forum.

Tact.ai is on a mission to help life science organizations nurture meaningful customer engagement through our human-friendly software. Our AI-powered engagement platform empowers field teams to work with their customers in new ways to drive better outcomes. Tact.ai is headquartered in Silicon Valley and is backed by some of the world’s leading firms in venture capital, technology, and healthcare and life sciences, including Microsoft’s venture fund M12, Salesforce Ventures, Novartis, Lilly and McKesson Ventures. Visit us at: https://www.tact.ai/

Dopavision is pioneering the development of innovative solutions that target the eye’s innate dopamine pathway to address unmet needs in ophthalmology using digitally delivered light. The Berlin-based start-up is developing a novel intervention for myopia that can be easily administered using a smartphone app. Dopavision’s goal is to provide a clinically validated intervention to help fight the global myopia crisis. Myopia – also known as nearsightedness – is the inability to see far away objects clearly. It commonly occurs due to excessive elongation of the eyeball during growth. This elongation causes incoming images to be focussed in front of the retina rather than on the retina. Myopia is a serious public health concern, expected to reach a global prevalence of 50% by 2050. Severe cases of myopia are associated with chronic sight-threatening conditions, including glaucoma, cataract, retinal detachment, and myopic maculopathy. Dopavision’s breakthrough technology targets children and young adolescents to address myopia early on and provide medical benefits for later years of life. The Company’s lead product, MyopiaX®, leverages a patented, light-based technology that stimulates specific photosensitive cells of the retina, which in turn modulate retinal dopamine, a key neurotransmitter involved in eye growth. Founded in 2017, Dopavision GmbH has raised €16.2 million in private equity and public grants, and is backed by Seventure Partners, Novartis Pharma (dRx Capital), Boehringer Ingelheim Venture Fund, and Ababax Health. Dopavision is also supported by the German Federal Ministry of Education and Research (BMBF) via the “Industrie-in-Klinik” program. Proceeds from the Company’s €12 million Series A financing round, which closed in July 2021, are being used to fund the clinical development of MyopiaX®, as well as ongoing scientific research and product development activities.

COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real-world data. By using our proprietary technology, advanced analytics and deep expertise to organize complex data, we provide a comprehensive picture of cancer that can be used to advance care and research. ‍We believe that everyone touched by cancer deserves a clear path to care. Together, we can make that vision a reality.

At H1, our mission is nothing short of creating a healthier future worldwide by unlocking and democratizing global access to critical expertise, HCP information, claims data, ground-breaking research and discoveries, and connected insights for all – doctors, researchers, industry and, ultimately, patients – bringing everyone closer together to advance medicine and clinical outcomes. Insights derived from H1’s solutions help life sciences and other healthcare organizations accelerate the development, launch, and dissemination of life-saving treatments, drive meaningful engagements with key opinion leaders, and help ensure equitable access to healthcare services.

Mekonos is a Silicon Valley Venture-backed Life Sciences company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in cell & gene therapies and cell line development.

Launched in the US in 2023, NuvoAir is a purpose-built, integrated specialty care platform that is reinventing the operating model through which care to complex cardiopulmonary patients is delivered. We emphasize the management of exacerbations, the key contributors to high healthcare costs and longitudinal care. Our platform empowers physicians, helping them maintain autonomy, deliver outstanding care and enhance their revenue in ways previously unattainable. By collaborating with health plans, risk-bearing entities, and innovative cardiologists and pulmonologists, we have redefined how patients with complex heart and lung issues, receive high quality care. To discover more about how NuvoAir is advancing high-value care in the cardiopulmonary space and to explore NuvoAirs extensive body of clinical evidence, visit nuvoair.com. Our recruiting email is talent@nuvoair.com, do not hesitate to reach out for any open position. Erin Murphree will be reaching out to you within short notice!

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.

Yseop is the leader in Generative AI for regulated industries, changing the way content automation solutions are delivered with a human-centric, AI platform. Yseop is reimagining the future of scientific writing to get medicine into the hands of those who need it faster. With a suite of industry-specific applications and cutting-edge hybrid Natural Language Generation (NLG) technology that blends symbolic, machine learning, and LLM techniques, Yseop ensures that even the most demanding content automation tasks are met with ease, scalability and application security across the entire enterprise. As the world’s leading content automation solution for biopharmaceuticals, Yseop Copilot is a digital colleague that empowers scientific writers and addresses the unique requirements of regulated industries. Blending the power of large language models with customer data, Yseop Copilot delivers trusted and auditable content automation solutions in a closed, secure environment.

We believe clinical research can be built to improve health equity globally. Learning if treatments are safe and effective for the people who need them requires us to offer studies that are more accessible and offer choice. We founded Lightship in 2018 with the inspiration to keep people at the heart of our work and use the latest innovations in digital health, technology, and remote care melded with high quality clinical research to transform clinical trials. Our approach offers clinical trials that are designed from the beginning to make it easier for patients and caregivers to take part. By using inclusive technology, flexible visit types, an amazing experience, and commitment to quality, we can develop programs to better bring new potentially life-saving therapies into the world, together.

Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave is currently collaborating with leading clinics, payers, and pharma companies across the country.

Healthcare providers no longer have to go to multiple portals or chase down the appropriate paperwork to complete the enrollment process. RxLightning serves as a single destination for healthcare providers to enroll patients for any specialty medication, brand or generic, at any specialty pharmacy. We strive to improve speed of access for patients to specialty medications, accelerating the delivery of your specialty products and maximizing your revenue stream. Our platform is a single solution that simplifies, streamlines and automates the complex and manual process of specialty medication enrollment across manufacturers, hubs, and specialty pharmacies. Specialty prescribing is complex. We make it simple. Digitized forms for 1,200+ specialty medications to get your patients started on the therapies they need at RxLightning speed. To view our open positions, view our careers page: https://jobs.gusto.com/boards/rxlightning-inc-2ba76134-6085-4789-bec7-35312efef93e

Holmusk is a data analytics and health technology company on a mission to harness real-world evidence to transform both research and care for behavioral health. Combining a leading behavioral health database with AI-powered analytics and digital solutions designed to address the most pressing challenges in behavioral health, Holmusk is advancing the frontier of evidence generation and fueling innovation. Holmusk’s core offerings include HolCare EHR+, an electronic health records platform with built-in measurement-based care, and NeuroBlu Research, a powerful data analytics solution that enables users to build patient cohorts, explore datasets, and discover new insights. Founded in 2015, Holmusk is a global company headquartered in Singapore and New York. Holmusk was recognized as a Technology Pioneer in 2019 by the World Economic Forum.